Furthermore, interrupting the association between DDX17/β-catenin and NF-κB with CXCR1/2 inhibitor would markedly reverse DDX17-mediated HCC proliferation and metastasis. This evidence concerns the gene CXCR1 and hepatocellular carcinoma.